Berlin Metropolitan Area
Business leader and CPTO with an 18-years track record in value creation, top-line growth, and market leadership across MedTech, Technology, and B2B sectors. Spearheaded GN’s global transformation (€2.4B Portfolio), delivering a €1Bn hearing business turnaround (+9% growth, 6.8pp EBIT expansion), capturing market share through innovative Edge-AI solutions, and realizing 15% post-merger synergies. Aligns commercial execution and technology, builds high-peforming global teams and executes value creation for Boards, investors, and global partners. Signature Achievements: 📈 Turnaround & EBITDA Growth: Orchestrated the revitalization of €1Bn GN Hearing business, steering the strategy that delivered 10% revenue growth and EBIT margin expansion by 6.8 pp. 🚀 M&A & Buy-and-Build: Directed the integration of a €2.4B revenue portfolio across 9 global sites, realizing 15% operational synergies post-merger. 💰 Carve-out & Exit: Played a pivotal leadership role in the complex Carve-out of Sivantos (ex-Siemens), driving operational improvements that fueled a 2x expansion in Enterprise Value at exit. 🤖 Innovation: Launched industry-defining Edge AI experiences and secured partnerships with Microsoft & Cochlear. Mandates: CEO in mid market or CPTO/CTO/COO in large cap in MedTech and Industrial Technology. Areas of Expertise: Strategy & Value Creation: P&L Responsibility • EBITDA Growth • Carve-outs • Due Diligence • Buy-and-Build • Post-Merger Integration (PMI) • Go-to-Market • Exit Readiness • Turnaround • Strategic Partnerships Industry: MedTech • HealthTech • Industrial Tech • Manufacturing • Edge AI • Consumer & Enterprise Tech • Wearables • Hearing Aids • Enterprise Headsets • Enterprise Video • Meeting Room Systems • Cardiac Devices (CRM) • Cochlear Implants • Class II/III Medical Devices Tech & Ops: Operations • Manufacturing • R&D (HW/SW/Semiconductors) • AI • Product Development • Capital Efficiency • Global Leadership (Europe / US / APAC) • Regulatory Strategy ✉️ [email protected]
€2.4B Revenue Portfolio | 1,300 FTEs (PM, R&D, Audiology, QA&RA) across 9 sites. Member of GN Executive Leadership Team. Directs and executes the €230M annual investment across Hearing, Enterprise, and Consumer sectors to maximize ROI and sustainable growth. 📈 Turnaround GN Hearing (€1B): Delivered 10% revenue growth and expanded EBIT margins by 6.8 pp via strict commercial and operational discipline. 🚀 Scale & Synergies: Directed the integration of a €2.4B portfolio, realizing 15% operational synergies 🤖 Edge AI: Innovation Leadership: Accelerated growth by launching industry-defining Edge AI experiences (ReSound Savia, Jabra Evolve 3, Jabra Panacast 40 VBS) and securing strategic partnerships with Microsoft, Cochlear, and global Semiconductor vendors. ---------------------------- GN Group is the global leader in audio and video solutions for Hearing and Enterprise/Consumer markets, known for brands including Jabra, ReSound and SteelSeries, €2.4B in revenue in 2024
Scope: €1B P&L | 600 FTEs leading PM, R&D, Clinical & Q&RA. Mandate: Halt market share decline (market position #4) and restore competitiveness. 📈 Growth Strategy: Steered and executed growth strategies by product line, region, channel, and key account plans to reverse the decline. 🔹 Transformation: Built a scalable organization with a focus on customer-centric innovation, quality & cost, laying the operational groundwork for the subsequent turnaround.
Defined growth and portfolio strategy, laying the groundwork for the hearing turnaround.
Scope: 40 FTEs | Class III Active Implants | Reported to President CRM | Competing vs. Medtronic, Boston Scientific, Abbott 🔹 Portfolio Strategy: Defined and executed global strategy for Class III active implants (pacemakers, ICDs, CRTs), delivering successful global launches. 🔹 Market Engagement: Managed global Key Opinion Leader (KOL) boards and drove market adoption. 🔹 Novel Therapy Innovation: Spearheaded development of a novel CE-approved therapy for conduction system pacing and a new clinical workflow for heart failure management. ----------------------- Privately held global cardiovascular medtech player, developing and manufacturing Class III active implants (pacemakers, ICDs, CRT, Homemonitoring) while competing head-to-head with industry leaders Medtronic, Boston Scientific, and Abbott
Scope: 250 FTEs across 3 global sites (Germany/Singapore) | Private Equity Carve-out (EQT). 💰 Exit Value Creation: Pivotal contribution to the Value Creation Plan (VCP) post-carve-out, fueling a ~2x expansion in Enterprise Value at merger. 🚀 Innovation Pipeline: Built a robust product engine (Styletto, Pure Charge&Go, Silk) that drove 14% revenue growth and a 3% market share gain, serving as the cornerstone of the equity story. ⚙️ Operational Excellence: Transformed R&D and Ops, shortening development cycles by 50% and executing aggressive cost-down initiatives (-30% COGS) to maximize EBITDA margins. ----------------------------- Global hearing healthcare business, formerly Siemens Audiology, spun out from Siemens in 2015 via a private-equity carve-out (EQT) and merged in 2018 to form WS Audiology, the world’s largest hearing aid manufacturer by unit volume.
Various roles in Strategy, Product Management, and R&D in Siemens Audiology Co-led development of a 3-yr turnaround plan at Siemens Audiology in preparation for carve-out. Closed critical technology gaps, supporting successful sale to EQT in 2014.